NASDAQ:OPRX

OptimizeRx Stock Forecast, Price & News

$48.53
+0.26 (+0.54 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$48.13
Now: $48.53
$50.75
50-Day Range
$41.99
MA: $48.84
$54.27
52-Week Range
$8.66
Now: $48.53
$63.98
Volume149,064 shs
Average Volume281,439 shs
Market Capitalization$815.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare. Its cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, and critical clinical information; and network consists of electronic health record company platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and clinical messaging services. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, it operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, the company offers patient programs with treatment and affordability information, lifestyle and condition trackers, Internet device connectivity, forms, and surveys. OptimizeRx Corporation is headquartered in Rochester, Michigan.
OptimizeRx logo

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6568
Employees71
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.60 million
Book Value$3.17 per share

Profitability

Net Income$-3,140,000.00

Miscellaneous

Market Cap$815.64 million
Next Earnings Date5/3/2021 (Estimated)
OptionableNot Optionable

Headlines

OptimizeRx Sees Unusually High Options Volume (NASDAQ:OPRX)
April 21, 2021 |  americanbankingnews.com
OptimizeRx (NASDAQ:OPRX) Sees Unusually-High Trading Volume
April 13, 2021 |  americanbankingnews.com
OptimizeRx (NASDAQ:OPRX) Stock Price Up 3.6%
April 12, 2021 |  americanbankingnews.com
OptimizeRx (NASDAQ:OPRX) Stock Price Up 5.6%
April 6, 2021 |  americanbankingnews.com
OptimizeRx (NASDAQ:OPRX) Stock Price Down 6%
April 5, 2021 |  americanbankingnews.com
2 Biotech Stocks That Could Be Millionaire Makers
April 4, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.49 out of 5 stars

Computer And Technology Sector

363rd out of 1,554 stocks

Business Services, Not Elsewhere Classified Industry

52nd out of 192 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$48.53
+0.26 (+0.54 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

What stocks does MarketBeat like better than OptimizeRx?

Wall Street analysts have given OptimizeRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptimizeRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for OptimizeRx
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Tuesday, February, 23rd. The company reported $0.16 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.16. The company had revenue of $16.43 million for the quarter, compared to the consensus estimate of $16.02 million. OptimizeRx had a negative net margin of 16.20% and a negative trailing twelve-month return on equity of 10.86%.
View OptimizeRx's earnings history
.

How has OptimizeRx's stock price been impacted by Coronavirus (COVID-19)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPRX shares have increased by 546.2% and is now trading at $48.53.
View which stocks have been most impacted by COVID-19
.

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16-16 million, compared to the consensus revenue estimate of $11.1 million.

What price target have analysts set for OPRX?

4 brokers have issued 1-year price objectives for OptimizeRx's stock. Their forecasts range from $54.00 to $85.00. On average, they anticipate OptimizeRx's share price to reach $69.75 in the next year. This suggests a possible upside of 43.7% from the stock's current price.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 52, Pay $626.59k)
  • Ms. Miriam J. Paramore, Pres & Chief Strategy Officer (Age 57, Pay $423.21k)
  • Mr. Stephen L. Silvestro, Chief Commercial Officer (Age 43, Pay $485.56k)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 64)
  • Mr. Todd Inman, Chief Technology Officer
  • Ms. Marion K Odence-Ford, Gen. Counsel & Chief Compliance Officer (Age 56)
  • Ms. Sheryl Kearney, HR Mang.
  • Mr. Terence J. Hamilton, Sr. VP of Pharma (Age 56)
  • Ms. Rebecca Whitney, Sr. VP of Commercial Operations
  • Mr. Angelo Campano, Sr. VP & Principal of Agency Channels

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology Group (MRVL), The Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Handelsinvest Investeringsforvaltning (0.65%), Calamos Advisors LLC (0.59%), Hillsdale Investment Management Inc. (0.57%) and Taylor Wealth Management Partners (0.12%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Gus D Halas and William J Febbo.
View institutional ownership trends for OptimizeRx
.

Which institutional investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning, and Taylor Wealth Management Partners. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or view top insider-selling stocks.

Which institutional investors are buying OptimizeRx stock?

OPRX stock was acquired by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., and Calamos Advisors LLC. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gregory D Wasson, Gus D Halas, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $48.53.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $815.64 million and generates $24.60 million in revenue each year. The company earns $-3,140,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 71 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

Where are OptimizeRx's headquarters?

OptimizeRx is headquartered at 400 WATER STREET SUITE 200, ROCHESTER MI, 48307.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]


This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.